Good Delivery Can Take You Everywhere

Aposense Molecular Nano-Motors (MNM) The First Gene Delivery Platform, Energized By The Internal Membrane Electrical Field.

About Us

Aposense is an Israeli publicly-traded biopharmaceutical company (TASE: APOS), specializing in development of novel drugs, utilizing membrane electrical forces, for trans-membrane of macromolecule drugs, mainly siRNA. The Company has full capacity research facilities and scientific leadership, headed by Professor Ilan Ziv and Professor Roger Kornberg, Nobel Prize Laureate, 2006.

Aposense is focused on a novel and powerful natural energy
resource: The Membrane Dipole Potential

Aposense pioneers in translational R&D of a recently-discovered voltage, that resides deep within any phospholipid membrane, and which is related to the membrane electric dipole potential.

Due to the high hydrophobicity of biological membranes, the dipole potential translates into an enormously strong electric field of up to 1 billion V/m (!), spanning ~30 Å, from membrane surface to membrane center.

Aposense Technology is the first utilization of this energy resource for medical or biotechnological applications, including trans-membrane delivery of genetic drugs, such as siRNA or ASO.

Fascinated by the fact that every cell harbors its own discrete and strong powerhouse, Aposense developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities, capable of “energy mining” from the Internal Membrane Electric Field, and its translation into kinetic energy, for movement within the hydrophobic membrane core.

Upon linkage to a genetic drug, this intra-membrane movement of the MNMs can be utilized for energy-consuming tasks, such as enabling the delivery of genetic therapeutics namely siRNA into the cytoplasm, where they exert their pharmacological effects, e.g., gene silencing.

These Molecular Nano-Motors (MNMs) are the core of our Technology

The MNMs are pharmaceutically-compatible, small-molecule chemical moieties (MW≈800 Daltons), capable of moving within the core of cell membranes, energized by the internal electric field. We can efficiently control the Intra-membrane movement of the MNMs pharmacologically, and respectively, enable and control the related trans-membrane transport of a genetic cargo drug linked to the MNM, with delivery into practically any cell type. Furthermore, our delivery system comprises an innovative detachment moiety, selectively activated upon entry into cells, releasing and liberating the intact macro-molecule drug in the cytoplasm, to exert its biological action, while the MNM is excreted through the urine or bile.

Translating the vision of genetic therapeutics into a “druggable” reality